Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients
Authors' conclusion
Radioiodine-avid metastatic disease detected by the second 131I is an infrequent finding in patients with BiR/InR after initial treatment. However, specific pathologic and biochemical features allow to better identify those cases with higher probability of developing SiR, thus improving the clinical effectiveness of performing a second 131I treatment.
Study context
- Population
- Patients with DTC and biochemical incomplete or indeterminate response (BiR/InR) after initial treatment who received a second 131I treatment
- Participants
- 153 patients
- Outcome
- Clinical impact of second 131I treatment (response category) and predictors of structural incomplete response (SiR)
Main finding
As reported in the abstract
Excellent response (ER)
11.8%
Structural incomplete response (SiR)
17%
BiR/InR persisted
71.2%
Observational data: associations, not effects.
Further findings
Radioiodine-avid metastases among SiR patients
- SiR patients with radioiodine-avid metastases
- 38.5%
Predictors of SiR
- SiR patients had larger tumor size and more frequently aggressive histology and vascular invasion than BiR/InR and ER
- Median LT4-Tg, rhTSH-stimulated Tg peak and thyroglobulin antibodies (TgAb) significantly higher in patients who developed SiR
Response at last evaluation · median: 9.9 years
- BiR/InR persisted
- 57.5%
- ER
- 26.2%
- SiR
- 16.3%
Further treatments after second 131I treatment
- Received further treatments
- 71/153 (46.4%)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →